SCHEMBL621024

SCHEMBL621024

NS(=O)(=O)c1ccccc1-n1cccn1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPK1 P28482 3/20 0.49
NPC1 O15118 1/20 0.49
CA2 P00918 10/20 0.46
CA1 P00915 8/20 0.46
CA9 Q16790 7/20 0.46
CA12 O43570 5/20 0.46
KDM4E B2RXH2 2/20 0.46
ALDH1A1 P00352 2/20 0.46
MEN1 O00255 1/20 0.46
LMNA P02545 1/20 0.46
GAA P10253 1/20 0.46
MAPT P10636 1/20 0.46
G6PD P11413 1/20 0.46
KMT2A Q03164 1/20 0.46
CA7 P43166 4/20 0.44
CA6 P23280 3/20 0.41
CA4 P22748 2/20 0.41
CA14 Q9ULX7 2/20 0.41
CA5A P35218 2/20 0.41
CA5B Q9Y2D0 2/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29484301 1.00 MAPK1 (0.49) MAPK1NPC1CA2CA1CA9
SCHEMBL8759101 0.83 MAPK1 (0.49) MAPK1NPC1KDM4EALDH1A1MEN1
SCHEMBL15266274 0.83 MAPK1 (0.49) MAPK1NPC1KDM4EALDH1A1MEN1
SCHEMBL10547713 0.83 MAPK1 (0.49) MAPK1NPC1KDM4EALDH1A1MEN1
SCHEMBL30183430 0.83 MAPK1 (0.49) MAPK1NPC1KDM4EALDH1A1MEN1
SCHEMBL8816241 0.81 MAPT (0.45) MAPK1NPC1CA2CA1CA9
SCHEMBL3478175 0.80 KDM4E (0.42) MAPK1NPC1CA2CA1CA9
SCHEMBL5602630 0.78 CA2 (0.45) MAPK1CA2CA1CA9CA12
SCHEMBL29718737 0.77 CA1 (0.46) MAPK1NPC1CA2CA1CA9
SCHEMBL4341886 0.77 MAPK1 (0.67) MAPK1NPC1KDM4EALDH1A1MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 166 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2005025510-A2 COX-2 SELECTIVE INHIBITOR WITH EXTENDED DURATION PHARMACIA CORPORATION (US) 2005-03-24 WO claimed
US-12103921-B2 Chemical compounds PFIZER INC. (US) 2024-10-01 US disclosed
US-20230382892-A1 Chemical Compounds PFIZER INC. (US) 2023-11-30 US disclosed
US-11702405-B2 Chemical compounds PFIZER INC. (US) 2023-07-18 US disclosed
US-20220348555-A1 Chemical Compounds PFIZER INC. (US) 2022-11-03 US disclosed
CN-107266425-B Pyrazol-1-yl benzene sulfonamides as CCR9 antagonists 坎莫森特里克斯公司 2020-03-03 CN disclosed
EP-3413889-A1 COMPOSITIONS INCLUDING BENZENESULFONAMIDE-CONTAINING NON-STEROIDAL ANTI-INFLAMMATORY DRUGS SILK FIBROIN AND A GELLING AGENT AND USES THEREOF Cocoon Biotech Inc. (US) 2018-12-19 EP disclosed
WO-2017139684-A1 COMPOSITIONS INCLUDING BENZENESULFONAMIDE-CONTAINING NON-STEROIDAL ANTI-INFLAMMATORY DRUGS SILK FIBROIN AND A GELLING AGENT AND USES THEREOF COCOON BIOTECH INC. (US) 2017-08-17 WO disclosed
US-8907101-B2 Sulfonamide derivatives PFIZER LIMITED (GB) 2014-12-09 US disclosed
US-8779090-B2 Methods and compositions for the treatment of heart failure and other disorders IRONWOOD PHARMACEUTICALS, INC. (US) 2014-07-15 US disclosed
WO-1998016227-A9 METHOD OF USING CYCLOOXYGENASE-2 INHIBITORS IN THE TREATMENT AND PREVENTION OF NEOPLASIA 1998-07-30 WO disclosed
WO-1998022101-A2 METHOD OF USING CYCLOOXYGENASE-2 INHIBITORS AS ANTI-ANGIOGENIC AGENTS G.D. SEARLE & CO. (US) 1998-05-28 WO disclosed
WO-1998016227-A1 METHOD OF USING CYCLOOXYGENASE-2 INHIBITORS IN THE TREATMENT AND PREVENTION OF NEOPLASIA G.D. SEARLE & CO. (US) 1998-04-23 WO disclosed
WO-1997011704-A1 SUBSTITUTED PYRAZOLYL BENZENESULFONAMIDES FOR USE IN VETERINARY THERAPIES AS ANTIINFLAMMATORY AGENTS G.D. SEARLE & CO. (US) 1997-04-03 WO disclosed
US-4810282-A 3-ORTHO-(ISOXAZOLYL,ISOTHIAZOLYL, PYRAZOLYL,THIADIAZOLYL, OXADIAZOLYL AND TRIAZOLYL BENZENESULFONUREYLENE-1,2,4-TRIAZOLES E. I. DU PONT DE NEMOURS AND COMPANY (US) 1989-03-07 US disclosed
EP-0083975-B1 HERBICIDAL SULFONAMIDES E.I. DU PONT DE NEMOURS AND COMPANY (US) 1987-11-19 EP disclosed
US-4695311-A Herbicidal sulfonamides E. I. DU PONT DE NEMOURS AND COMPANY (US) 1987-09-22 US disclosed
US-4606755-A Herbicidal sulfonamides E. I. DU PONT DE NEMOURS AND COMPANY (US) 1986-08-19 US disclosed
US-4511392-A N--/PYRIMIDIN-2-YLAMINOCARBENYL/-HETERO-SUBSTITUETED BENZENSESULFO E. I. DU PONT DE NEMOURS AND COMPANY (US) 1985-04-16 US disclosed
EP-0083975-A2 Herbicidal sulfonamides E.I. DU PONT DE NEMOURS AND COMPANY (US) 1983-07-20 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11702405-B2 Chemical compounds HBZ, HBB, HBS1L MAPK1 2425/4885NPC1 2812/4885CA2 3113/4885
US-20230382892-A1 Chemical Compounds HBZ, HBB, HBS1L MAPK1 2425/4885NPC1 2812/4885CA2 3113/4885
US-12103921-B2 Chemical compounds HBZ, HBB, HBS1L MAPK1 2425/4885NPC1 2812/4885CA2 3113/4885
US-20220348555-A1 Chemical Compounds HBZ, HBB, HBS1L MAPK1 2425/4885NPC1 2812/4885CA2 3113/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.